Skip to main content
PMC home page
Gut logoLink to Gut
. 2000 Sep;47(3):320–325. doi: 10.1136/gut.47.3.320

COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors

B WHITTLE 1
PMCID: PMC1728030  PMID: 10940262

Full Text

The Full Text of this article is available as a PDF (111.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes C. J., Cameron I. L., Hardman W. E., Lee M. Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Br J Cancer. 1998 Feb;77(4):573–580. doi: 10.1038/bjc.1998.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barnes C. J., Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology. 1998 May;114(5):873–877. doi: 10.1016/s0016-5085(98)70305-1. [DOI] [PubMed] [Google Scholar]
  3. Bennett A., Houghton J., Leaper D. J., Stamford I. F. Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins. 1979 Feb;17(2):179–191. doi: 10.1016/0090-6980(79)90037-6. [DOI] [PubMed] [Google Scholar]
  4. Bensen W. G., Fiechtner J. J., McMillen J. I., Zhao W. W., Yu S. S., Woods E. M., Hubbard R. C., Isakson P. C., Verburg K. M., Geis G. S. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999 Nov;74(11):1095–1105. doi: 10.4065/74.11.1095. [DOI] [PubMed] [Google Scholar]
  5. Bianchi Porro G., Lazzaroni M., Manzionna G., Petrillo M. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther. 1998 Apr;12(4):355–360. doi: 10.1046/j.1365-2036.1998.00312.x. [DOI] [PubMed] [Google Scholar]
  6. Bjarnason I., Zanelli G., Smith T., Prouse P., Williams P., Smethurst P., Delacey G., Gumpel M. J., Levi A. J. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology. 1987 Sep;93(3):480–489. doi: 10.1016/0016-5085(87)90909-7. [DOI] [PubMed] [Google Scholar]
  7. DAVENPORT H. W. GASTRIC MUCOSAL INJURY BY FATTY AND ACETYLSALICYLIC ACIDS. Gastroenterology. 1964 Mar;46:245–253. [PubMed] [Google Scholar]
  8. Dequeker J., Hawkey C., Kahan A., Steinbrück K., Alegre C., Baumelou E., Bégaud B., Isomäki H., Littlejohn G., Mau J. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998 Sep;37(9):946–951. doi: 10.1093/rheumatology/37.9.946. [DOI] [PubMed] [Google Scholar]
  9. DuBois R. N., Giardiello F. M., Smalley W. E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am. 1996 Dec;25(4):773–791. doi: 10.1016/s0889-8553(05)70274-0. [DOI] [PubMed] [Google Scholar]
  10. Emery P., Zeidler H., Kvien T. K., Guslandi M., Naudin R., Stead H., Verburg K. M., Isakson P. C., Hubbard R. C., Geis G. S. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999 Dec 18;354(9196):2106–2111. doi: 10.1016/S0140-6736(99)02332-6. [DOI] [PubMed] [Google Scholar]
  11. Farrow D. C., Vaughan T. L., Hansten P. D., Stanford J. L., Risch H. A., Gammon M. D., Chow W. H., Dubrow R., Ahsan H., Mayne S. T. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97–102. [PubMed] [Google Scholar]
  12. Fries J. F., Miller S. R., Spitz P. W., Williams C. A., Hubert H. B., Bloch D. A. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):647–655. doi: 10.1016/s0016-5085(89)80061-7. [DOI] [PubMed] [Google Scholar]
  13. Fu J. Y., Masferrer J. L., Seibert K., Raz A., Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990 Oct 5;265(28):16737–16740. [PubMed] [Google Scholar]
  14. Giardiello F. M., Offerhaus G. J., DuBois R. N. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1071–1076. doi: 10.1016/0959-8049(95)00137-8. [DOI] [PubMed] [Google Scholar]
  15. Giovannucci E., Rimm E. B., Stampfer M. J., Colditz G. A., Ascherio A., Willett W. C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994 Aug 15;121(4):241–246. doi: 10.7326/0003-4819-121-4-199408150-00001. [DOI] [PubMed] [Google Scholar]
  16. Giraud M. N., Motta C., Romero J. J., Bommelaer G., Lichtenberger L. M. Interaction of indomethacin and naproxen with gastric surface-active phospholipids: a possible mechanism for the gastric toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs). Biochem Pharmacol. 1999 Feb 1;57(3):247–254. doi: 10.1016/s0006-2952(98)00303-7. [DOI] [PubMed] [Google Scholar]
  17. Goldman A. P., Williams C. S., Sheng H., Lamps L. W., Williams V. P., Pairet M., Morrow J. D., DuBois R. N. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis. 1998 Dec;19(12):2195–2199. doi: 10.1093/carcin/19.12.2195. [DOI] [PubMed] [Google Scholar]
  18. Hawkey C. J. COX-2 inhibitors. Lancet. 1999 Jan 23;353(9149):307–314. doi: 10.1016/s0140-6736(98)12154-2. [DOI] [PubMed] [Google Scholar]
  19. Hawkey C., Kahan A., Steinbrück K., Alegre C., Baumelou E., Bégaud B., Dequeker J., Isomäki H., Littlejohn G., Mau J. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol. 1998 Sep;37(9):937–945. doi: 10.1093/rheumatology/37.9.937. [DOI] [PubMed] [Google Scholar]
  20. Jones M. K., Wang H., Peskar B. M., Levin E., Itani R. M., Sarfeh I. J., Tarnawski A. S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999 Dec;5(12):1418–1423. doi: 10.1038/70995. [DOI] [PubMed] [Google Scholar]
  21. Laine L., Harper S., Simon T., Bath R., Johanson J., Schwartz H., Stern S., Quan H., Bolognese J. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology. 1999 Oct;117(4):776–783. doi: 10.1016/s0016-5085(99)70334-3. [DOI] [PubMed] [Google Scholar]
  22. Langman M. J., Jensen D. M., Watson D. J., Harper S. E., Zhao P. L., Quan H., Bolognese J. A., Simon T. J. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999 Nov 24;282(20):1929–1933. doi: 10.1001/jama.282.20.1929. [DOI] [PubMed] [Google Scholar]
  23. Langman M. J., Weil J., Wainwright P., Lawson D. H., Rawlins M. D., Logan R. F., Murphy M., Vessey M. P., Colin-Jones D. G. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994 Apr 30;343(8905):1075–1078. doi: 10.1016/s0140-6736(94)90185-6. [DOI] [PubMed] [Google Scholar]
  24. Lesch C. A., Kraus E. R., Sanchez B., Gilbertsen R., Guglietta A. Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis. Methods Find Exp Clin Pharmacol. 1999 Mar;21(2):99–104. doi: 10.1358/mf.1999.21.2.529236. [DOI] [PubMed] [Google Scholar]
  25. Llenas J. Aceclofenac: is the antiinflammatory effect really due to cyclooxygenase inhibition? J Rheumatol. 1999 Sep;26(9):2064–2065. [PubMed] [Google Scholar]
  26. Lücker P. W., Pawlowski C., Friedrich I., Faiella F., Magni E. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm. 1994;14(2):29–38. [PubMed] [Google Scholar]
  27. Mitchell J. A., Warner T. D. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol. 1999 Nov;128(6):1121–1132. doi: 10.1038/sj.bjp.0702897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Morrison B. W., Christensen S., Yuan W., Brown J., Amlani S., Seidenberg B. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther. 1999 Jun;21(6):943–953. doi: 10.1016/S0149-2918(99)80016-2. [DOI] [PubMed] [Google Scholar]
  29. Nakatsugi S., Fukutake M., Takahashi M., Fukuda K., Isoi T., Taniguchi Y., Sugimura T., Wakabayashi K. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn J Cancer Res. 1997 Dec;88(12):1117–1120. doi: 10.1111/j.1349-7006.1997.tb00337.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Neustadt D. H. Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol Suppl. 1997 Feb;47:17–22. [PubMed] [Google Scholar]
  31. O'Banion M. K., Sadowski H. B., Winn V., Young D. A. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem. 1991 Dec 5;266(34):23261–23267. [PubMed] [Google Scholar]
  32. Panara M. R., Renda G., Sciulli M. G., Santini G., Di Giamberardino M., Rotondo M. T., Tacconelli S., Seta F., Patrono C., Patrignani P. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276–280. [PubMed] [Google Scholar]
  33. Reddy B. S., Hirose Y., Lubet R., Steele V., Kelloff G., Paulson S., Seibert K., Rao C. V. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000 Jan 15;60(2):293–297. [PubMed] [Google Scholar]
  34. Reuter B. K., Asfaha S., Buret A., Sharkey K. A., Wallace J. L. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest. 1996 Nov 1;98(9):2076–2085. doi: 10.1172/JCI119013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Robert A. An intestinal disease produced experimentally by a prostaglandin deficiency. Gastroenterology. 1975 Oct;69(4):1045–1047. [PubMed] [Google Scholar]
  36. Robert A., Nezamis J. E., Lancaster C., Hanchar A. J. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology. 1979 Sep;77(3):433–443. [PubMed] [Google Scholar]
  37. Russell R. I. Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins. Rheumatol Int. 1990;10 (Suppl):17–21. doi: 10.1007/BF02274751. [DOI] [PubMed] [Google Scholar]
  38. Sano H., Kawahito Y., Wilder R. L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995 Sep 1;55(17):3785–3789. [PubMed] [Google Scholar]
  39. Schmassmann A., Peskar B. M., Stettler C., Netzer P., Stroff T., Flogerzi B., Halter F. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol. 1998 Mar;123(5):795–804. doi: 10.1038/sj.bjp.0701672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Schnitzer T. J., Ballard I. M., Constantine G., McDonald P. Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. Clin Ther. 1995 Jul-Aug;17(4):602–612. doi: 10.1016/0149-2918(95)80037-9. [DOI] [PubMed] [Google Scholar]
  41. Schnitzer T. J., Constantine G. Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. J Rheumatol Suppl. 1997 Feb;47:23–31. [PubMed] [Google Scholar]
  42. Shah A. A., Murray F. E., Fitzgerald D. J. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. Rheumatology (Oxford) 1999 May;38 (Suppl 1):19–23. doi: 10.1093/rheumatology/38.suppl_1.19. [DOI] [PubMed] [Google Scholar]
  43. Sheng H., Shao J., Kirkland S. C., Isakson P., Coffey R. J., Morrow J., Beauchamp R. D., DuBois R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 1997 May 1;99(9):2254–2259. doi: 10.1172/JCI119400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sigthorsson G., Tibble J., Hayllar J., Menzies I., Macpherson A., Moots R., Scott D., Gumpel M. J., Bjarnason I. Intestinal permeability and inflammation in patients on NSAIDs. Gut. 1998 Oct;43(4):506–511. doi: 10.1136/gut.43.4.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Simon L. S., Weaver A. L., Graham D. Y., Kivitz A. J., Lipsky P. E., Hubbard R. C., Isakson P. C., Verburg K. M., Yu S. S., Zhao W. W. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999 Nov 24;282(20):1921–1928. doi: 10.1001/jama.282.20.1921. [DOI] [PubMed] [Google Scholar]
  46. Simon L. S., Zhao S. Z., Arguelles L. M., Lefkowith J. B., Dedhiya S. D., Fort J. G., Johnson K. E. Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis. Clin Ther. 1998 Nov-Dec;20(6):1218–1193. doi: 10.1016/s0149-2918(98)80117-3. [DOI] [PubMed] [Google Scholar]
  47. Smalley W., Ray W. A., Daugherty J., Griffin M. R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med. 1999 Jan 25;159(2):161–166. doi: 10.1001/archinte.159.2.161. [DOI] [PubMed] [Google Scholar]
  48. Smith C. J., Zhang Y., Koboldt C. M., Muhammad J., Zweifel B. S., Shaffer A., Talley J. J., Masferrer J. L., Seibert K., Isakson P. C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313–13318. doi: 10.1073/pnas.95.22.13313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  50. Waddell W. R., Loughry R. W. Sulindac for polyposis of the colon. J Surg Oncol. 1983 Sep;24(1):83–87. doi: 10.1002/jso.2930240119. [DOI] [PubMed] [Google Scholar]
  51. Wallace J. L., Keenan C. M., Granger D. N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol. 1990 Sep;259(3 Pt 1):G462–G467. doi: 10.1152/ajpgi.1990.259.3.G462. [DOI] [PubMed] [Google Scholar]
  52. Wallace J. L. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology. 1997 Mar;112(3):1000–1016. doi: 10.1053/gast.1997.v112.pm9041264. [DOI] [PubMed] [Google Scholar]
  53. Warner T. D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J. A., Vane J. R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563–7568. doi: 10.1073/pnas.96.13.7563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Whittle B. J., Higgs G. A., Eakins K. E., Moncada S., Vane J. R. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature. 1980 Mar 20;284(5753):271–273. doi: 10.1038/284271a0. [DOI] [PubMed] [Google Scholar]
  55. Whittle B. J., László F., Evans S. M., Moncada S. Induction of nitric oxide synthase and microvascular injury in the rat jejunum provoked by indomethacin. Br J Pharmacol. 1995 Oct;116(4):2286–2290. doi: 10.1111/j.1476-5381.1995.tb15066.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Whittle B. J. Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology. 1981 Jan;80(1):94–98. [PubMed] [Google Scholar]
  57. Wober W. Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide. Rheumatology (Oxford) 1999 May;38 (Suppl 1):33–38. doi: 10.1093/rheumatology/38.suppl_1.33. [DOI] [PubMed] [Google Scholar]
  58. Xie W. L., Chipman J. G., Robertson D. L., Erikson R. L., Simmons D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2692–2696. doi: 10.1073/pnas.88.7.2692. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES